Efficacy of continuous in-wound infusion of levobupivacaine and ketorolac for post-caesarean section analgesia: a prospective, randomised, double-blind, placebo-controlled trial

Table 3 Total consumption of piritramide across the four parturient groups, at 12, 24 and 48 h

Parturient group	Time	Total consumption of piritramide (mg)				p-value
Parturient group	(h)	Median	Minimum	Maximum	95% CI	p-value
Levobupivacaine alone	12	8	0	16	8–14	ns
	24	10	0	34	8–14	0.015^a (vs combination)
	48	14	0	34	8–22	0.021^a (vs combination)
Ketorolac tromethamine alone	12	4	0	16	2–10	ns
	24	4	0	18	4–16	0.003^a (vs saline placebo)
	48	4	0	20	4–16	0.001^a (vs saline placebo)
Combination	12	2	0	10	2–6	ns
	24	2	0	14	0–8	< 0.001^a (vs saline placebo) 0.015^a (vs levobupivacaine)
	48	4	0	18	2–10	< 0.001^a (vs saline placebo) 0.021^a (vs levobupivacaine)
Saline placebo	12	10	4	38	6–16	ns
	24	16	6	50	10–22	0.003^a (vs ketorolac tromethamine) < 0.001^a (vs combination)
	48	24	8	76	16–30	0.001^a (vs ketorolac tromethamine) < 0.001^a (vs combination)

CI confidence interval
^asignificant difference among groups calculated using ANOVA/ Kruskal Wallis tests, and between groups comparison post-hoc tests with Bonferroni correction; ns, non-significant

ISSN: 1471-2253